The latest price trends and market dynamics of teclistamab in 2025

Teritolumab (Teclistamab) is a bispecific T cell-directed antibody drug that targets relapsed or refractory multiple myeloma (RRMM) and can simultaneously bind CD3 (T cell surface molecule) and BCMA (B cell maturation antigen), thereby activating the patient's own T cells to target and kill myeloma cells. It was first approved for marketing by the FDA and EMA in 2022, and has since been sold in many countries. In 2025, teritusumab will be officially launched in mainland China, marking a new treatment option for domestic high-risk myeloma patients. However, it has not yet been included in the national medical insurance directory, and the price issue has become the focus of patients.

According to public market information, the generic drug Teritusumab has been put on the market in many foreign countries. The price of a box of 153mg/1.7ml injection is about RMB 50,000 or more. The price mainly reflects the research and development costs and clinical application value of its innovative biological agents, especially in the field of relapsed/refractory myeloma. For patients who have failed multiple treatments in the past, teritusumab has demonstrated considerable response rates and survival benefits, and is one of the important breakthroughs in current T cell-directed therapies.

In the Chinese market, although teritusumab is already available in some large tertiary hospitals or oncology hospitals, patients have to bear high costs because it has not yet entered the medical insurance system. The actual domestic selling price is close to the international price, and the selling price in some areas is even higher. The cost of a single treatment may be as high as tens of thousands of yuan, and long-term treatment will constitute a huge financial burden. Currently, some patients are calling for it to be included in the national medical insurance directory or to introduce charity assistance projects to improve drug accessibility. At the same time, with the advancement of relevant medical insurance negotiations and the development of domestic alternative therapies, prices are expected to gradually fall in the future.

In terms of market dynamics, as the global bispecific antibody research and development boom continues, the international clinical application of teritusumab is continuously expanding, covering third-line to fifth-line myeloma treatment options. At the same time, in China, many local biopharmaceutical companies are developing similar BCMA/CD3 targeted dual-antibody drugs, trying to form a competitive advantage in terms of price and accessibility. 2025In the second half of 2025, with the accumulation of local data in China, medical insurance negotiations and the clinical advancement of local alternatives, the domestic price and market structure of teritusumab are expected to adjust, bringing more treatment and economic options to patients.

Reference materials:https://www.drugs.com/